Close Menu

NEW YORK – Quidel announced preliminary second quarter results after the market closed Monday, saying that it expects to report a revenue increase in the range of 86 to 87 percent over the prior-year quarter. The firm attributed the increase to demand for its COVID-19-related diagnostic products.

Quidel said it expects revenues for Q2 2020 to be in the range of $201 million to $202 million. The firm's revenues for Q2 2019 were $108.3 million, as previously reported.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.